Preview

Качественная клиническая практика

Расширенный поиск

Обзор возможностей медикаментозной терапии нарушения сексуальных функций у женщин

Полный текст:

Аннотация

В половом акте женщины играют роль такие аспекты, как ее внутреннее сексуальное состояние, внешний сексуальный образ, а также такие составляющие факторы, как семья, общество, культура и окружающая среда. Определенное значение в этом принадлежит опыту сексуальных отношений, имевшиеся партнеры, психическое состояние, заболевания, гормональный статус, психогенные и органические причины нарушений сексуального влечения, возбуждения, оргазма и половых болевых нарушений, вызывающих у человека стресс. Нет оснований считать, что большинство женщин увязывают удовлетворение половым актом с количеством достигнутых оргазмов или даже с вероятностью достижения оргазма при данном половом акте. В настоящее время разрабатываются 6 основных путей медикаментозного лечения нарушений сексуальных функций и/или симптомов менопаузы у женщин. 

Об авторе

С. Редакционная

Россия


Список литературы

1. Alcantarra AG. A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. J Sex Marital Ther 1999; 25 (2): 125-9

2. American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994

3. Antares Pharma [online]. Available from URL: http://www.antarespharma.com/content/news/news_06062001.html [Accessed 2003 Apr 16]

4. Arlt W, Callies F, Vlumen JCV, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341 (14): 1013-20

5. Avis N, Stellato R, Crawford S, et al. Is there an association between menopause status and sexual functioning? Menopause 2000; 7 (5): 297-309

6. Avis N. Sexual function and aging in men and women: community and population-based studies. J Gend Specif Med 2000; 3 (2): 37-41

7. Bachmann G, Bancroft J, Braunstein G, et al. Androgen deficiency in women: definition, diagnosis and classification. Princeton Meeting; 2001 Jun 29; Princeton (NJ)

8. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77 (4): 660-5

9. Bancroft J, Graham CA, McCord C. Conceptualizing women’s sexual problems. J Sex Marital Ther 2001; 27: 95-103

10. Bancroft J. State of the art lecture: inhibitory mechanisms in men and women. First Annual Comprehensive Review of Sexual Medicine; 2002 Apr 18-21; Vancouver

11. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896-902

12. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classification. J Urol 2000 Mar; 163: 888-93

13. Basson R, Bourgeois-Law G, Fourcroy J, et al. Androgen ‘deficiency’ in women is problematic. Med Aspects Hum Sex 2001 Sep; 1 (6): 41-3

14. Basson R, McInnes R, Smoith M, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11 (4): 367-77

15. Basson R. Expand the concepts of the human sex response cycle. J Sex Marital Ther 2001; 27 (1): 33-44

16. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996 Apr; 23 (3): 259-63

17. Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, crossover, placebo-controlled study. Br J Obstet Gynaecol 2001; 108: 623-8

18. Cellegy Pharmaceuticals Inc [online]. Available from URL: http://www.cellegy.com/ [Accessed 2003 Apr 16]

19. Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep 2002 Jun; 2 (3): 182-7

20. Crenshaw TL, Goldberg JP. Dopaminergic drugs. In: Crenshaw TL, Goldberg JP, editors. Sexual pharmacology. New York: WW Norton & Company, 1996: 369-88

21. Deliganis AV, Maravilla KR, Heiman JR, et al. Female genitalia: dynamic MR imaging with use of MS-325: initial experiences evaluating female sexual response. Radiology 2002; 225 (3): 791-9

22. Derogatis L, Rosen R, Leiblum S, et al. The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002; 28 (4): 317-30

23. Foreman MM, Hall JL. Effects of D2-dopaminergic receptor stimulation on male rat sexual behavior. J Neural Transm 1987; 68: 153-70

24. Foreman MM. Disorders of sexual response: pioneering new pharmaceutical and therapeutic opportunities. Expert Opin Investig Drugs 1995; 4 (7): 621-36

25. Fourcroy J. Issues and priorities in the development of drug treatments for female sexual dysfunction. Int J Impot Res 1998; 10 Suppl. 2: S121-S3

26. Fourcroy JL. Androgens and desire pharmacology in women: syllabus and presentation. First Annual Comprehensive Review of Sexual Medicine; 2002 Apr 18-21; Vancouver

27. Frank E, Anderson C, Rubenstein D. Frequency of sexual dysfunction in normal couples. N Engl J Med 1978; 299: 111-5

28. Gitlin MJ, Sun R, Altshuler L, et al. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther 2002 Mar-Apr; 28 (2): 131-8

29. Gittelman M, Costabile RA, Peterson C, et al. In clinic evaluation of the safety and efficacy of topical alprostadil (PGE1) for the treatment of female sexual dysfunction [abstract 603]. J Urol 2002; 167 (4): 151

30. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction: Sildenatfil Study Group. N Engl J Med 1998; 338 (20): 1397-404

31. Grumbach MM, Ducharme JR, Moloshok RE. On the fetal masculination action of certain oral progestins. J Clin Endocrinol Metab 1959; 19: 1369-80

32. Heaton J. New classification system for erectile dysfunction therapies. J Androl 1998; 19 (4): 399-404

33. Heiman H. Presentation: psychophysiological measurement perspective. First Annual Comprehensive Review of Sexual Medicine; 2002 Apr 18-21; Vancouver

34. Heiman JR. Female sexual response patterns: interactions of physiological, affective, and contextual cues. Arch Gen Psychiatry 1980 Nov 11; 37: 1311-6

35. Islam A, Mitchel JT, Rosen R, et al. Topical alprostadil in the treatment of female sexual arousal disorder: a pilot study. J Sex Marital Ther 2001; 27: 541-9

36. Ito T, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther 2001; 27 (5): 541-9

37. Jensvold MF, Plaut VC, Rojansky N, et al. Sexual side effects of psychotropic drugs in women and men. In: Jensvold MF, Halbreich U, Hamilton JA, editors. Psychopharmacology and women. Washington, DC: American Psychiatric Press Inc, 1996: 323-68

38. Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999; 53: 481-6

39. Kingsberg SA. The impact of aging on sexual function in women and their partners. Arch Sex Behav 2002; 31 (5): 431-7

40. Kirk JM, Perry LA, Shand WS, et al. Female pseudohermaphroditism due to a maternal adrenocortical tumor. J Clin Encrocrinol Metab 1990; 70: 1280-4

41. Krane R, Brock G, Eardley I, et al. Committee 8 oral non-endocrine treatment. In: Jardin A, Wagner G, Khoury S, et al., editors. Erectile dysfunction. Plymouth: Plymbridge Distributors Ltd, 2000: 730

42. Laan E, Everaerd W. Physiological measures of vaginal vasocongestion. Int J Impot Res 1998 May; 10 Suppl. 2: S107-10

43. Laan E, van Lunsen RHW, Everaerd W, et al. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Womens Health Gend Based Med 2002; 11 (4): 357-66

44. Laumann E, Michael R, Michaels S, et al. The social organization of sexuality. Chicago (IL): University of Chicago Press, 1994

45. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States; prevalence and predictors. JAMA 1999; 281 (6): 537-44

46. Mazer NA. Testosterone deficiency in women: etiologies, diagnosis, and emerging treatments. Int J Fertil 2002; 47 (2): 77-86

47. Meston CM, Worcel M. The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Arch Sex Behav 2002; 31 (4): 323-32

48. Miller KK. Androgen deficiency in women. J Clin Endocrinol Metab 2001; 86: 2395-401

49. Moore KL, Persaud T. The developing human. 6th ed. Philadelphia (PA): WB Saunders, 1998: 563

50. NexMed (USA), Inc. [online]. Available from URL: http://www.nexmed.com/press/news118.htm [Accessed 2003 May 29]

51. Novavax, Inc. [online]. Available from URL: http://www.novavax.com/womens.html [Accessed 2003 May 29]

52. Noven Pharmaceuticals, Inc. [online]. Available from URL: http://www.noven.com/research.htm [Accessed 2003 May 29]

53. O’Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson’s disease. Mov Disord 1998; 13 (3): 536-9

54. Organization of medical consultations. ICUD – NGO in official relationship with the World Health Organization, International Society of Urology, and International Society for Sexual and Impotence Research [online]. Available from URL: http://www.congress-urology.org/[Accessed 2003 Apr 16]

55. Palatin Technologies [online]. Available from URL: http://www.palatin.com/ [Accessed 2003 April 16]

56. Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (estratest and estratest HS) replacement therapy in the United States. Clin Ther 1997; 19 (5): 1070-84

57. Physicians Desk Reference (PDR). 57th ed. Montvale (NJ): Thomson PDR, 2003

58. Quirk F, Heiman J, Rosen R, et al. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med 2002 Apr; 11 (3): 277-89

59. Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208

60. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85

61. Rosen RC, Phillips NA, Gendrano NC. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther 1999; 25: 137-44

62. Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril 2002; 77 Suppl. 5: S89-93

63. Rubio-Aurioles E, Lopez M, Lipezker M, et al. Phentolamine mesylate in postmenopausal women with female sexual arousal disorder: a psychophysiological study. J Sex Marital Ther 2002; 28 Suppl. 1: 205-15

64. Rubio-Aurioles E, Rampazzo C, Hurley D, et al. Combination therapy for female arousal disorder: a clinical trial to evaluate the efficacy of a combination of phentolamine mesylate and apomorphine in the subjective response to video sexual stimulation [abstract]. Female Sexual Function Forum; 2001 Oct 25-28; Boston (MA), 84

65. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343 (10): 682-8

66. Simons J, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001; 30 (2): 177-219

67. Sipski ML, Rosen RC, Alexander CJ, et al. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injuries. Urology 2000; 55: 812-5

68. The National Council on Aging [online]. Available from URL: http://www.ncoa.org/content.cfm?sectionID=105&detail=128 [Accessed 2003 Apr 16]

69. US Food and Drug Administration. Guidance for Industry. Female sexual dysfunction: clinical development of drug products for treatment [online]. Available from URL: http://www.fda.gov/cder/guidance/3312dft.htm [Accessed Apr 16]

70. Wessells H, Fuclarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998; 160 (2): 389-93

71. Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56 (4): 641-6

72. Women’s Health Initiative Clinical Trial Writing Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288 (3): 321-33

73. Padma-Nailutn H et al. Efficacy and safety of topical alprostaclil cream for the treatment of female sexual arousal disorder (FSAD) a double-blind, multicenter, randomized, and placebo-controlled clinical trial. J Sex Marital Tlier 29 (5): 329-44, 2003.

74. NexMed to initiate 400 Femrox? clinical study in China for female sexual arousal disorder (FSAD) [press release]. PR Newswire via NewEdge: 1 p, 3 Mar 2004.

75. Pacher P., Mabley J.C., Liaudet L., Evgenov O.V., Southan Cr.J., Abdelkarim G.E., Szabo C., Salzman A.I,. Topical administration of novel nitric oxide donor, linear polyethylenimine-nitric oxide/nucleophile adduct (DSI), selectively increases vaginal blood flow in anesthetized rats. Int J Impotence Res 15 (6) 461-4, Dec 2003.


Для цитирования:


Редакционная С. Обзор возможностей медикаментозной терапии нарушения сексуальных функций у женщин. Качественная клиническая практика. 2003;(4):2-10.

For citation:


. . Kachestvennaya klinicheskaya praktika. 2003;(4):2-10. (In Russ.)

Просмотров: 15


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)